Monoclonal gammopathy of undetermined significance (MGUS) is a highly prevalent disorder characterized by a small bone marrow plasma cell or lymphoplasmacytic clone (less than 10%) that produces a small amount of monoclonal paraprotein without associated organ damage. Most patients with MGUS display benign behavior indefinitely, but some progress to an overt malignancy, and others develop organ damage despite no increase in monoclonal protein, resulting in the so-called MG of clinical significance (MGCS). This concept includes different disorders depending on the organ involved, and among them, MG of neurological significance (MGNS) constitutes a real challenge from both a diagnostic and therapeutic point of view. Diagnosis is particularly difficult due to MGNS's heterogeneous clinical presentation and common lack of a diagnostic biopsy. On the other hand, the complexity of treatment lies in the lack of standardized regimens and the common irreversibility of neurological damage. Focusing on the neurological manifestations of MGUS affecting the peripheral nervous system, we describe 3 illustrative cases from daily practice and discuss different aspects of diagnosis to treatment, emphasizing the need for multidisciplinary management based on the close collaboration of neurologists and hematologists.

1.
Rajkumar
SV
,
Dimopoulos
MA
,
Palumbo
A
, et al.
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
.
Lancet Oncol
.
2014
;
15
(
12
):
e538
-
e548
.
2.
Campo
E
,
Jaffe
ES
,
Cook
JR
, et al.
The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee
.
Blood
.
2022
;
140
(
11
):
1229
-
1253
.
3.
Fermand
JP
,
Bridoux
F
,
Dispenzieri
A
, et al.
Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications
.
Blood
.
2018
;
132
(
14
):
1478
-
1485
.
4.
Visentin
A
,
Pravato
S
,
Castellani
F
, et al.
From biology to treatment of monoclonal gammopathies of neurological significance
.
Cancers (Basel)
.
2022
;
14
(
6
):
1562
.
5.
Leung
N
,
Bridoux
F
,
Batuman
V
, et al.
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
.
Nat Rev Nephrol
.
2019
;
15
(
1
):
45
-
59
.
6.
Moreno
DF
,
Rosiñol
L
,
Cibeira
MT
,
Bladé
J
,
Fernández de Larrea
C.
Treatment of patients with monoclonal gammopathy of clinical significance
.
Cancers (Basel)
.
2021
;
13
(
20
):
5131
.
7.
Kelly
JJ
Jr
,
Kyle
RA
,
O'Brien
PC
,
Dyck
PJ
.
Prevalence of monoclonal protein in peripheral neuropathy
.
Neurology
.
1981
;
31
(
11
):
1480
-
1483
.
8.
Castillo
JJ
,
Callander
NS
,
Baljevic
M
,
Sborov
DW
,
Kumar
S.
The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance
.
Am J Hematol
.
2021
;
96
(
7
):
846
-
853
.
9.
Traub
R
,
Qarni
T
,
Cohen
AD
,
Karam
C.
Paraproteinemic neuropathies
.
Muscle Nerve
.
2024
;
70
(
2
):
173
-
179
.
10.
Rögnvaldsson
S
,
Steingrímsson
V
,
Turesson
I
,
Björkholm
M
,
Landgren
O
,
Yngvi Kristinsson
S.
Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls
.
Haematologica
.
2020
;
105
(
11
):
2679
-
2681
.
11.
D'Sa
S
,
Kersten
MJ
,
Castillo
JJ
, et al.
Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 Consensus Panel
.
Br J Haematol
.
2017
;
176
(
5
):
728
-
742
.
12.
Khwaja
J
,
D'Sa
S
,
Minnema
MC
,
Kersten
MJ
,
Wechalekar
A
,
Vos
JM
.
IgM monoclonal gammopathies of clinical significance: diagnosis and management
.
Haematologica
.
2022
;
107
(
9
):
2037
-
2050
.
13.
Vos
JM
,
Notermans
NC
,
D'Sa
S
, et al.
High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy
.
J Neurol Neurosurg Psychiatry
.
2018
;
89
(
9
):
1007
-
1009
.
14.
Delmont
E
,
Attarian
S
,
Antoine
JC
, et al.
Relevance of anti-HNK1 antibodies in the management of anti-MAG neuropathies
.
J Neurol
.
2019
;
266
(
8
):
1973
-
1979
.
15.
Mariotto
S
,
de Gaspari
P
,
Jäger
D
, et al.
A novel cell-based immunofluorescence assay for the detection of autoantibodies to myelin-associated glycoprotein
.
Front Neurol
.
2023
;
14
:
1289810
.
16.
Willison
HJ
,
O'Leary
CP
,
Veitch
J
, et al.
The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies
.
Brain
.
2001
;
124
(
pt 10
):
1968
-
1977
.
17.
Notermans
NC
,
Franssen
H
,
Eurelings
M
,
Van der Graaf
Y
,
Wokke
JH
.
Diagnostic criteria for demyelinating polyneuropathy associated with monoclonal gammopathy
.
Muscle Nerve
.
2000
;
23
(
1
):
73
-
79
.
18.
Dakalas
M.
Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies
.
Ther Adv Neurol Disord
.
2018
;
11
:
1756285617746640
.
19.
Dalakas
MC
,
Rakocevic
G
,
Salajegheh
M
, et al.
Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy
.
Ann Neurol
.
2009
;
65
(
3
):
286
-
293
.
20.
Léger
JM
,
Viala
K
,
Nicolas
G
, et al
;
RIMAG Study Group (France and Switzerland)
.
Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy
.
Neurology
.
2013
;
80
(
24
):
2217
-
2225
.
21.
Lunn
MP
,
Nobile-Orazio
E.
Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies
.
Cochrane Database Syst Rev
.
2016
;
10
(
10
):
CD002827
.
22.
Nobile-Orazio
E
,
Bianco
M
,
Nozza
A.
Advances in the treatment of paraproteinemic neuropathy
.
Curr Treat Options Neurol
.
2017
;
19
(
12
):
43
.
23.
Colchester
NTH
,
Allen
D
,
Katifi
HA
, et al.
Chemoimmunotherapy with rituximab, cyclophosphamide and prednisolone in IgM paraproteinaemic neuropathy: evidence of sustained improvement in electrophysiological, serological and functional outcomes
.
Haematologica
.
2021
;
106
(
1
):
302
-
305
.
24.
Treon
SP
,
Tripsas
CK
,
Meid
K
, et al.
Ibrutinib in previously treated Waldenström's macroglobulinemia
.
N Engl J Med
.
2015
;
372
(
15
):
1430
-
1440
.
25.
Castellani
F
,
Visentin
A
,
Campagnolo
M
, et al.
The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy
.
Neurol Neuroimmunol Neuroinflamm
.
2020
;
7
(
4
):
e720
.
26.
Sarosiek
SR
,
Branagan
AR
,
Doughty
C
, et al.
Prospective study of acalabrutinib with rituximab in patients with symptomatic anti-MAG mediated IgM peripheral neuropathy
.
Blood
.
2023
;
142
(
suppl 1
):
213
.
27.
Katz
JS
,
Saperstein
DS
,
Gronseth
G
,
Amato
AA
,
Barohn
RJ
.
Distal acquired demyelinating symmetric neuropathy
.
Neurology
.
2000
;
54
(
3
):
615
-
620
.
28.
Chaudhry
HM
,
Mauermann
ML
,
Rajkumar
SV
.
Monoclonal gammopathy-associated peripheral neuropathy: diagnosis and management
.
Mayo Clin Proc
.
2017
;
92
(
5
):
838
-
850
.
29.
Bardwick
PA
,
Zvaifler
NJ
,
Gill
GN
, et al.
Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes: the POEMS syndrome
.
Medicine (Baltimore)
.
1980
;
59
(
4
):
311
-
322
.
30.
Mauermann
ML
,
Sorenson
EJ
,
Dispenzieri
A
, et al.
Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP
.
J Neurol Neurosurg Psychiatry
.
2012
;
83
(
5
):
480
-
486
.
31.
Dispenzieri
A
,
Kyle
RA
,
Lacy
MQ
, et al.
POEMS syndrome: definitions and long-term outcome
.
Blood
.
2003
;
101
(
7
):
2496
-
2506
.
32.
Dispenzieri
A.
POEMS syndrome: update on diagnosis, risk-stratification, and management
.
Am J Hematol
.
2023
;
98
(
12
):
1934
-
1950
.
33.
Humeniuk
MS
,
Gertz
MA
,
Lacy
MQ
, et al.
Outcomes of patients with POEMS syndrome treated initially with radiation
.
Blood
.
2013
;
122
(
1
):
68
-
73
.
34.
D'Souza
A
,
Lacy
M
,
Gertz
M
, et al.
Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience
.
Blood
.
2012
;
120
(
1
):
56
-
62
.
35.
Cook
G
,
Iacobelli
S
,
van Biezen
A
, et al.
High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder Sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation
.
Haematologica
.
2017
;
102
(
1
):
160
-
167
.
36.
Zhao
H
,
Huang
XF
,
Gao
XM
, et al.
What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone?
Leukemia
.
2019
;
33
(
4
):
1023
-
1029
.
37.
Li
J
,
Huang
XF
,
Cai
QQ
, et al.
A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome
.
Am J Hematol
.
2018
;
93
(
6
):
803
-
809
.
38.
Gavriatopoulou
M
,
Ntanasis-Stathopoulos
I
,
Fotiou
D
, et al.
Upfront daratumumab with lenalidomide and dexamethasone for POEMS syndrome
.
Hemasphere
.
2020
;
4
(
3
):
e381
.
39.
Hilton
DA
,
Jacob
J
,
Househam
L
,
Tengah
C.
Complications following sural and peroneal nerve biopsies
.
J Neurol Neurosurg Psychiatry
.
2007
;
78
(
11
):
1271
-
1272
.
40.
Wechalekar
AD
,
Cibeira
MT
,
Gibbs
SD
, et al.
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA Working Group
.
Amyloid
.
2023
;
30
(
1
):
3
-
17
.
41.
Sanchorawala
V
,
Boccadoro
M
,
Gertz
M
, et al.
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA Working Group guidelines
.
Amyloid
.
2022
;
29
(
1
):
1
-
7
.
42.
Van Schaik
IN
,
Léger
JM
,
Nobile-Orazio
E
, et al.
European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision
.
J Peripher Nerv Syst
.
2010
;
15
(
4
):
295
-
301
.
43.
Price
R
,
Smith
D
,
Franklin
G
, et al.
Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary. Report of the AAN Guideline Subcommittee
.
Neurology
.
2022
;
98
(
1
):
31
-
43
.
44.
Beydoun
SR
,
Darki
L.
Paraproteinemic neuropathies
.
Continuum (Minneapolis)
.
2023
;
29
(
5
):
1492
-
1513
.
You do not currently have access to this content.